Axim Biotechnologies (OP: AXIM )

0.4200 USD +0.0100 (+2.44%)

Official Closing Price Updated: 12:59 PM EST, Nov 27, 2020 Add to My Watchlist

Price and Volume

Volume	79,200
Open	0.4100
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.4100
Today's Range	0.4100 - 0.4349
52wk Range	0.1000 - 1.440
Shares Outstanding	56,736,450
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity

November 10, 2020

AXIM® Biotechnologies Issues Update Letter to Shareholders

October 28, 2020

Performance

YTD	-6.67%	-6.67%
1 Month	-12.95%	-12.95%
3 Month	-33.86%	-33.86%
6 Month	-16.83%	-16.83%
1 Year	-1.18%	-1.18%

More News

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)

October 06, 2020

Medical Marijuana, Inc. Investment Company AXIM Biotechnologies Files Patent for Worlds First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)

October 06, 2020

AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing

September 30, 2020

AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19

September 29, 2020

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1

September 22, 2020

AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies

September 16, 2020

AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test

August 24, 2020

Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute

August 11, 2020

AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19

August 05, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.